We analyzed the prognostic impact of levels of free light chains (FLC) in 106 patients with DLBCL, selecting 61 patients with a monoclonal (M) protein in serum, and 45 patients without a M protein as an IPI-matched control group. Patients with a M protein had higher levels of FLC, but these were not of prognostic significance in this group. The presence of a M protein nullified associations of κ-FLC with several laboratory parameters indicating immune system activation observed in patients without a M protein. Patients without M protein and κ-FLC >50 mg/L had a significant inferior event-free survival (p =.004). The presence of M protein of an IgM type at diagnosis was a negative outcome predictor (p =.008), while a non-IgM M protein did not significantly impact on prognosis. In conclusion, the prognostic performance of the FLC assay is altered by the presence of a M protein.
Maiolo, E., Alma, E., Napodano, C., Gulli, F., Bellesi, S., Cuccaro, A., Pocino, K., D'Alo', F., Iachini, M., Martini, M., Larocca, L. M., De Stefano, V., Basile, U., Hohaus, S., The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL), <<LEUKEMIA & LYMPHOMA>>, 2020; 61 (5): 1133-1139-1139. [doi:10.1080/10428194.2019.1706731] [http://hdl.handle.net/10807/152275]
The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL)
Maiolo, E.;Alma, E.;Napodano, C.;Bellesi, S.;Cuccaro, A.;Pocino, K.;D'Alo', F.;Iachini, M.;Martini, M.;Larocca, L. M.;De Stefano, V.;Basile, U.;Hohaus, S.
2019
Abstract
We analyzed the prognostic impact of levels of free light chains (FLC) in 106 patients with DLBCL, selecting 61 patients with a monoclonal (M) protein in serum, and 45 patients without a M protein as an IPI-matched control group. Patients with a M protein had higher levels of FLC, but these were not of prognostic significance in this group. The presence of a M protein nullified associations of κ-FLC with several laboratory parameters indicating immune system activation observed in patients without a M protein. Patients without M protein and κ-FLC >50 mg/L had a significant inferior event-free survival (p =.004). The presence of M protein of an IgM type at diagnosis was a negative outcome predictor (p =.008), while a non-IgM M protein did not significantly impact on prognosis. In conclusion, the prognostic performance of the FLC assay is altered by the presence of a M protein.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
